Stereotactic Body Radiotherapy for Isolated Para-aortic Lymph Node Recurrence after Curative Resection in Gastric Cancer by Kim, Mi-Sook et al.
INTRODUCTION 
Gastric cancer is the most common malignancy in Korea
(1). Early detection, surgical technique refinements, and appro-
priate adjuvant therapy have improved the survival rates of
primary gastric cancer patients. However, despite recent ad-
vances, gastric cancer is still the second most leading cause
of cancer-related death in Japan (2) and Korea (1), and even
after complete surgical resection, a substantial proportion of
patients succumb to local recurrence or distant metastasis. 
Lymph node (LN) metastasis is one of the most important
prognostic factors after stomach resection (3). Appropriate
extent of lymph node dissection during surgery has been de-
batable. Though the randomized trials did not support the
routine use of extended LN dissection (4, 5), the possibility
for extended LN dissection to decrease locoregional recurrences
seems plausible. Nashimoto et al. (6) reported that paraaor-
tic lymph node (PALN) metastasis was detected in 25% of
gastric cancer patients that had undergone extensive lym-
phadenectomy, and that the 5-yr survival rate of these patients
was 23.1%. Other institutes have reported corresponding 5-
yr survival rates of 15.2% (7), 16.0% (8), and 18.6% (9) for
gastric cancer patients with PALN metastasis, respectively.
Peritoneal recurrence is regarded to be the most common
type of recurrence after gastric cancer surgery, followed by
hematogenous, local, and regional recurrence. When recur-
rence is discovered after radical surgery in gastric cancer, no
standard salvage treatment has been established yet for such
patients. This is because almost all recurrent gastric cancers
represent advanced cancer progression, such as, peritoneal seed-
ing or extensive LN metastasis. However, few studies (10-12)
have been performed on liver resection for metastatic gastric
cancer, although it is known that fewer patients with gastric
liver metastases are good candidates for resection than among
those with metastases from colorectal cancer. Koga et al. (13)
reported outstanding 5-yr survival rate of 42% post-diagnosis
after the complete resection of isolated liver recurrence, and
8 (19%) of the 42 patients involved remained alive for over
5 yr after the initial hepatectomy. Therefore, we hypothesized
that some selected cases among patients with localized gas-
tric recurrences, as like recurrent colorectal cancer, might have
indolent disease course and be salvaged by local treatment
even the number of cases is limited. The aim of this study
was to investigate whether stereotactic body radiotherapy
(SBRT) can salvage gastric cancer patients with PALN recur-
rence. Accordingly, we reviewed 7 patients who underwent
SBRT for isolated PALN recurrence from gastric cancer to
clarify patient outcome.
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Stereotactic Body Radiotherapy for Isolated Para-aortic Lymph Node
Recurrence after Curative Resection in Gastric Cancer 
The aim of this study was to investigate whether stereotactic body radiotherapy
(SBRT) can salvage gastric cancer patients with para-aortic lymph node (PALN)
recurrence. From January 2003 to December 2006, 7 patients were treated for iso-
lated PALN recurrence from gastric cancer after curative resection. Follow up dura-
tions ranged from 19 to 33 months (median; 26 months), and SBRT doses from 45
Gy to 51 Gy (median 48 Gy) in 3 fractions. Disease progression-free and overall
survivals and toxicities were recorded. Response to treatment was assessed by com-
puted tomography. Final patient outcomes were as follows: 2 were alive without evi-
dence of disease, 3 remained alive with disease, and 2 patients died of disease. Five
of 7 patients showed complete response and 2 patients partial response between
3 and 11 months after SBRT. Three-year overall and disease progression-free sur-
vival rates post-SBRT were 43% and 29%, respectively. No severe complication
was detected during follow-up. Selected patients with isolated PALN recurrence
can be salvaged by SBRT without severe complications.
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MATERIALS AND METHODS
Patients 
From January 2003 to December 2006, 7 patients with
isolated PALN recurrence from gastric cancer after curative
resection were treated with SBRT using a CyberKnife (Accu-
ray Inc., Sunnyvale, CA, U.S.A.). Isolated PALN recurrence
was initially detected by computed tomography (CT), and was
confirm by elevated standardized uptake values on a paraaortic
lesion by positron emission tomography (PET) or PET/CT.
Patient characteristics are summarized in Table 1. Briefly,
patient ages ranged from 41 to 68 yr (median 56), and the
male:female ratio was 5:2. All patients underwent subtotal
or total gastrectomy. Adjuvant chemotherapy was performed
in 4 patients. Initial pathologic stages were; stage II in 2, stage
III in 3, and stage IV in 2. Pathologic diagnoses were poorly
differentiated adenocarcinoma or signet ring cell carcinoma
in 5 patients and moderately differentiated adenocarcinoma
in 2. Interval between operation and first relapse ranged from
10 to 40 months (median 22 months). Six patients showed
a conglomerated LN and the other (case 6) had two separate
enlarged lymph nodes on a paraaortic lesion. Greatest tumor
diameters and heights were obtained after delineating tumors
on CT scans during planning, and are itemized in Table 1.
Recurrent tumor volumes ranged from 5.6 to 83 mL (medi-
an 21 mL). After recurrence had been detected, all patients
received chemotherapy based on 5-FU before SBRT. 
SBRT technique 
SBRT doses ranged from 45 to 51 Gy (median 48 Gy) and
were administered in 3 fractions. For SBRT, we used gold
fiducials (4 mm long and 0.8 mm in diameter) as markers
for tumor localization. Six fiducials were placed percutaneous-
ly at transverse processes of the spine located nearest tumors
using an 18 gauge spinal needle under fluoroscopic guidance.
Patients were immobilized using an Alpha Cradle (Smithers
Medical Products, North Canton, OH, U.S.A.) for 5-7 days
after fiducial placement. Panning CT scans were performed
with patients in the treatment position, and these images were
then processed for the CyberKnife planning system. Gross
tumor volume (GTV) determined based on CT tumor visu-
alizations. To better delineate tumor volume, PET/CT images
were used as a reference. Planned target volumes (PTV) were
GTV plus a 2-3 mm margin. Radiation doses were prescribed
to the 80-83% isodose line of the maximum dose covering
the PTV (Fig. 1).
Survival, response, and toxicity assessments
Overall survival was calculated from the start date of SBRT
using the Kaplan-Meier method; median values are report-
ed. Disease progression free survival was also measured from
date of the first SBRT to the date of local progression, dis-
tant metastasis, or both. All statistical calculations were per-
formed using SPSS, version 13.0 (SPSS, Inc., Chicago, IL,
U.S.A.).
On CT scans, complete response (CR) was defined as com-
plete tumor resolution without new lesion development. Par-
tial response (PR) was defined as at least a 50% volume reduc-
tion of conglomerated or distinct tumors without new lesion
development. Stable disease (SD) was defined as a change in
tumor volume ranging from <50% reduction to <25% in-
*Latent time, disease free interval from operation to first relapse; 
� F/U, Follow-up duration.
GTV, Gross tumor volume; CR, complete response; PR, partial response; LN, lymph node; Rt, right; Lt, left; SCL, supraclavicular lymph node; PALN,
paraaortic lymph node; DOD, died of disease; AWD, alive with disease; CDF, continuously disease-free; SBRT, Stereotactic body radiotherapy.
Case
Age
/sex
Pathology
Initial
staging
Adjuvant
chemother-
apy
Tumor size
(longest 
D* height)
GTV
(mL)
Final
status
F/U
�
(months)
Disease 
progression
site
Response
of tumor
(months
after SBRT)
Radiation
dose
(Gy)
Latent
time*
Table 1. Demographic and clinical data of the 7 patients
1 52/M P/D III Yes 10 3.5*4.0 13 48 CR (11) - 26 CDF
2 60/M P/D II No 17 6.0*5.9 83 45 CR (5) - 33 CDF
3 68/F P/D IV Yes 22 2.5*2.0 5.6 48 CR (3) Rt retrocural LN,  23 AWD
mediastinal LN,
Lt SCL LN
4 49/M M/D III No 29 4.0*3.9 21 48 CR (5) PALN, Bone 25 AWD
5 59/M M/D IV Yes 15 3.0*6.2 18 48 PR (3) PALN, 31 AWD
common iliac LN 
6 41/M P/D II No 40 4.0*2.6 21 45 CR (3) Local recur 32 DOD
2.5*1.3 subcutaneous
multiple brain
SCL LN
7 56/F P/D III Yes 25 4.2*4.0 36 51 PR (5) Liver, peritoneum 14 DOD490 M.-S. Kim, S.Y. Yoo, C.K. Cho, et al.
crease. Progressive disease (PD) was defined as an increase in
tumor size of ≥25%. Local progression was defined as in-
crease in tumor size of before CT image or the development
of a new lesion in the radiation field. 
Acute and late toxicities were defined as symptoms that
developed within or after 3 months of treatment completion,
respectively. 
RESULTS
Follow up ranged from 14 to 33 months (median; 26 mon-
ths). Final outcomes were as follows: 2 patients were alive
without evidence of disease; 3 remained alive with disease;
and 2 patients died of disease (Table 1). Case 7 developed soli-
tary liver metastasis at 5 months after SBRT and subsequent
peritoneal seeding, and died after 9 months. However, no
local progression in the radiation field was observed in this
patient until final follow up. The remaining 5 patients sur-
vived longer than 20 months (range; 23-33 months). Among
them, two patients (Case 1 and 2) did not show recurrence
for 26 and 33 months, respectively. Case 3 developed nodal
metastasis in the mediastinal and left supraclavicular areas.
Case 4 had PALN metastasis located outside the radiothera-
py field and a single bone metastasis, and received repeat
SBRT to PALN as well as bone metastasis. Case 5 also devel-
oped nodal metastasis in PALN and in the common iliac area.
Case 6 developed local relapse at 23 months after SBRT, and
died after 9 months due to multiple brain metastases with
leptomenigeal seeding.
On CT scans, 5 of the 7 patients showed complete response
and 2 patients partial response between 3-11 months post
first SBRT session. The 3-yr overall survival and disease pro-
gression free survival rates were 43% and 29%, respectively
(Fig. 2). Grade I acute toxicity such as nausea and vomiting
was observed in 2 patients at the first date of SBRT, and reliev-
ed without medication. And late complication was not detect-
ed during follow-up period.
DISCUSSION 
Peritoneal recurrence or hematogenous metastasis are com-
mon type of recurrence after surgery for gastric cancer, and,
if extensive LN dissection performed, isolated lymphogenous
recurrences are not frequently observed. Roderich et al. (14)
reported distant hematogenous metastasis only in 13 (18%)
of 73 patients, and peritoneal seeding alone in 8 (11%), and
locoregional alone in 2 (3%). Yoo et al. (15) reported peri-
toneal recurrence alone in 172 (33.9%) of 508 recurrent pa-
tients, hematogenous metastasis alone in 133 (26.2%), and
locoregional recurrence alone in 98 (19.3%). In these series,
most recurrence appeared diffusely at distant or peritoneal
sites, and most locoregional recurrences occurred in conjunc-
tion with relapse at extraregional sites.
For recurrent gastric cancer after curative resection, repeat
surgery was conducted in 12-20% of recurrent gastric cancer
patients, as a salvage treatment for local recurrence, for an
isolated liver/lung metastasis or for a single peritoneal mass,
or for palliative purposes to relieve gastrointestinal obstruc-
tion, obstructive jaundice, or ureter obstruction (16-18). Then,
50-85% of patients with re-operation underwent a palliative
procedure (17, 18). Park et al. (18) reported 86 reoperation
experiences in recurrent gastric cancer. The operative mor-
tality rate was 9 (10.5%) in 86 patients. Excluding the mor-
tality cases, among 77 patients, complete resection was pos-
sible in only 13 (17%) patients, and these 13 patients achi-
eved a 50% 5-yr survival rate and a median survival of 21
months, whereas 13 patients that underwent simple laparo-
Fig. 1. Planning of 48 Gy SBRT. Gross tumor volume (GTV) was
defined as the volume (mL) of the visible LN (innermost line). Ra-
diation dose was prescribed to the 80% isodose line of the maxi-
mum dose covering the GTV plus a 2 mm margin. The outermost
line is the 30% isodose line.
Fig. 2. Three-year overall survival (OS) and disease progression-
free survival rates (DPFS) were 43% and 29%, res- pectively.
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tomy without any aid had a median survival of only 3.8 mon-
ths. The other 51 patients received palliative procedure and
achieved a median survival of 7.8 months. Ha et al. (19) re-
ported that 241 (20%) of 1,223 gastric cancer patients who
underwent curative gastric resection recurred over a 13 yr
follow up. In their study, median survival durations were 7,
9.5, and 12.5 months, respectively after the detection of peri-
toneal seeding, hematogenous metastasis, and locoregional
recurrence. However, extent of resection was not specified.
Recently, several studies (20, 21) investigated the therapeu-
tic efficacy of combinatorial chemotherapy in recurrent gas-
tric cancer, and demonstrated excellent responses in a limit-
ed number of cases. However, because the numbers of pati-
ents enrolled were small and follow up durations were short,
further trials must be undertaken to evaluate the role of che-
motherapy.
Conventional radiotherapy has played a limited palliative
role in the treatment of recurrent gastric cancer involving
locoregional recurrence, especially PALN. The proximity
between involved lymph nodes and critical organs, such as,
the spinal cord, intestine, and colon, often prevents the deliv-
ery of sufficient radiation dose for local control when conven-
tional radiation modalities are used. However, SBRT is an
emerging technology in the radiation oncology field. This
system utilizes stereotactic principles of localization and mul-
tiple beams to target lesions accurately. SBRT can deliver
higher doses to tumor and cause less tissue damage than other
methods. Furthermore, it can have three times the biologi-
cal effect of fractionated radiation therapy.
Reports on salvage treatment for isolated PALN metastasis
are rare. Nashimoto et al. (6) reported a case with a disease-
free survival of 6 yr after the dissection of recurrent abdomi-
nal PALN in gastric cancer. Also Teraishi et al. (22) report-
ed a recurrence case of gastric cancer with PALN metastasis
that showed a marked response to systemic chemotherapy
consisting of S-1 alone. After chemotherapy, the patient has
remained in remission for more than 21 months with no severe
adverse events. In the present study, two (29%) among 7 pa-
tients achieved disease free survivals of 26 and 33 months
(from the start date of SBRT) without complications, and
only one patient showed local progression at 23 months after
SBRT. In these studies about PALN recurrence from gastric
cancer treated by operation, chemotherapy or SBRT, existence
of long term survivors seems to assist our hypothesis which
selected cases among recurrent gastric cancer patients with
isolated metastasis, as like recurrent colorectal cancer, may
have indolent disease course and be salvaged by adjustable
treatments.
In conclusion, the present study reports that selected iso-
lated PALN recurrence can be salvaged by SBRT without
severe complications. However, further studies are required
to confirm our preliminary results in a large number of pa-
tients.
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